Category: isoxazole

Synthesis of novel bicyclic 2-amino-4(1H)-pyridones. Reaction of lactim ethers with α-cyanoacetone dianion was written by Jiang, Jack B.;Urbanski, Maud J.. And the article was included in Tetrahedron Letters in 1985.Category: isoxazole This article mentions the following:

Lactim ethers I (X = S, bond; Z = O,S; n = 1-4), treated with C^–H₂COC^–HCN followed by MeOH, yielded bicyclic 2-amino-4(1H)-pyridones II. The dianion was generated in situ by treating 5-methylisoxazole with LiN(CHMe₂)₂. In the absence of MeOH ring closure did not occur. O-, N-, And C-alkylation of II was demonstrated. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Category: isoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.Category: isoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor was written by Zhao, Yujun;Zhou, Bing;Bai, Longchuan;Liu, Liu;Yang, Chao-Yie;Meagher, Jennifer L.;Stuckey, Jeanne A.;McEachern, Donna;Przybranowski, Sally;Wang, Mi;Ran, Xu;Aguilar, Angelo;Hu, Yang;Kampf, Jeff W.;Li, Xiaoqin;Zhao, Ting;Li, Siwei;Wen, Bo;Sun, Duxin;Wang, Shaomeng. And the article was included in Journal of Medicinal Chemistry in 2018.COA of Formula: C20H16ClN3O2 This article mentions the following:

We report the structure-based discovery of CF53 (28) as a highly potent and orally active inhibitor of bromodomain and extra-terminal (BET) proteins. By the incorporation of a NH-pyrazole group into the 9H-pyrimido[4,5-b]indole core, we identified a series of compounds that bind to BRD4 BD1 protein with K_i values of <1 nM and achieve low nanomolar potencies in the cell growth inhibition of leukemia and breast cancer cells. The most-promising compound, CF53, possesses excellent oral pharmacokinetic properties and achieves significant antitumor activity in both triple-neg. breast cancer and acute leukemia xenograft models in mice. Determination of the co-crystal structure of CF53 with the BRD4 BD1 protein provides a structural basis for its high binding affinity to BET proteins. CF53 is very selective over non-BET bromodomain-containing proteins. These data establish CF53 as a potent, selective, and orally active BET inhibitor, which warrants further evaluation for advanced preclin. development. In the experiment, the researchers used many compounds, for example, (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7COA of Formula: C20H16ClN3O2).

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.COA of Formula: C20H16ClN3O2

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF₁ receptor antagonists was written by Huang, Charles Q.;Wilcoxen, Keith M.;Grigoriadis, Dimitri E.;McCarthy, James R.;Chen, Chen. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2004.Electric Literature of C4H5NO This article mentions the following:

A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R¹ = Cl, O₂N, Me, F₃C, H₂N, HO, etc.; R² = H, Me, Cl, O₂N, H₂N, MeO, NO, etc.; R³, R⁴ = n-Pr, n-Bu, MeOCH₂CH₂, cyclopropylmethyl, PhCH₂] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF₁) receptor. Several compounds such as I [R¹ = Me₂N; R² = Me; R³ = R⁴ = n-Pr; (II)] (K_i = 10 nM) exhibited good binding affinities at the CRF₁ receptor. In addition, II had adequate solubility in water. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Electric Literature of C4H5NO).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Isoxazoles are potent isosteres of pyridine and have been found to inhibit voltage-gated sodium channels for pain control, for the construction of tetracycline antibiotic derivatives, and as a therapeutic agent for depression.Electric Literature of C4H5NO

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction was written by Buckley, Dennis L.;Van Molle, Inge;Gareiss, Peter C.;Tae, Hyun Seop;Michel, Julien;Noblin, Devin J.;Jorgensen, William L.;Ciulli, Alessio;Crews, Craig M.. And the article was included in Journal of the American Chemical Society in 2012.Product Details of 19668-85-0 This article mentions the following:

E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity. However, the development of small-mol. inhibitors has proven extraordinarily challenging as modulation of E3 ligase activities requires the targeting of protein-protein interactions. Using rational design, we have generated the first small mol. targeting the von Hippel-Lindau protein (VHL), the substrate recognition subunit of an E3 ligase, and an important target in cancer, chronic anemia, and ischemia. We have also obtained the crystal structure of VHL bound to our most potent inhibitor, confirming that the compound mimics the binding mode of the transcription factor HIF-1α, a substrate of VHL. These results have the potential to guide future development of improved lead compounds as therapeutics for the treatment of chronic anemia and ischemia. In the experiment, the researchers used many compounds, for example, 3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0Product Details of 19668-85-0).

3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Product Details of 19668-85-0

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Enthalpies of combustion and formation of 3-methylisoxazole and 5-methylisoxazole was written by Hamilton, Walter S.;Benton, Susan;French, Jennifer;McCormick, Deborah;Pustejovsky, Sharon;Thompson, Patricia. And the article was included in Journal of Chemical and Engineering Data in 1978.HPLC of Formula: 5765-44-6 This article mentions the following:

The enthalpies of combustion of 3-methylisoxazole [30842-90-1] and 5-methylisoxazole [5765-44-6] were measured by precision O-bomb calorimetry. The following values, based on the mass of sample burned, are reported for the standard enthalpy of combustion, ΔH°_c (298.15 K)/kcal_th mol^-1, of these compounds in the liquid state: 3-methylisoxazole, -546.00 ± 0.14; 5-methylisoxazole, -545.65 ± 0.17. Enthalpies of vaporization, determined calorimetrically, are 3-methylisoxazole, 9.51 ± 0.05 kcal mol^-1, and 5-methylisoxazole, 9.48 ± 0.04 kcal mol^-1. These data were used to calculate standard enthalpies of formation for the gaseous compounds, ΔH°_f(g), which are 3-methylisoxazole, 8.52 ± 0.16 kcal mol^-1, and 5-methylisoxazole, 8.14 ± 0.18 kcal mol^-1. Throughout this paper cal_th = 4.184 J and atm = 101.325 kPa. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6HPLC of Formula: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.HPLC of Formula: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Tailoring lipid nanoconstructs for the oral delivery of paliperidone: Formulation, optimization and in vitro evaluation was written by Rehman, Saleha;Nabi, Bushra;Baboota, Sanjula;Ali, Javed. And the article was included in Chemistry and Physics of Lipids in 2021.Electric Literature of C23H27FN4O3 This article mentions the following:

The present research work involves Quality by Design (QbD)-based fabrication of lipid nanoconstructs (LNC) of paliperidone (PPD) bearing superior biopharmaceutical attributes. LNC of paliperidone was prepared by melt emulsification-probe sonication and high-pressure homogenization method followed by optimization using QbD approach. Preparing LNC by both these methods will give the benefit of identifying the best optimized formulation which will be further evaluated for in vitro studies. The best optimized formulation was obtained using melt emulsification-probe sonication technique with small particle size (86.35 nm), high entrapment efficiency (90.07%), and high loading capacity (8.49%). The drug release from LNC was found to be 5, 8, and 9-folds greater than drug suspension in pH 1.2, 6.8, and 7.4 resp. (p < 0.001). Stability studies of LNC in simulated gastric fluid pH 1.2 and fasted state simulated intestinal fluid depicted no alteration in particle size and polydispersity index of LNC but were found to increase in fed state simulated intestinal fluid. The drug permeability through rat intestine for LNC was found to be approx. 6-folds (p < 0.05) greater as compared to the drug suspension which was further confirmed by confocal microscopy. The in vitro lipolysis study presented significantly highest solubilization (p < 0.001) in the aqueous phase thereby anticipating higher in vivo absorption. Thus, it was concluded that LNC bears the knack of improving the solubilization and permeation potential of an otherwise hydrophobic drug, paliperidone. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Electric Literature of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Electric Literature of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Synthesis of some polyheterocyclic systems with isolated nuclei was written by Martin, Nazario;Quinteiro, Margarita;Seoane, Carlos;Soto, Jose L.. And the article was included in Revista de la Real Academia de Ciencias Exactas, Fisicas y Naturales de Madrid in 1987.Safety of 5-Methylisoxazole This article mentions the following:

Knoevenagel-type condensation reactions of heterocyclic aldehydes were carried out. Thus, treatment of RCHO (R = pyridyl, pyrrolyl, furyl, etc.) with active methylene compounds PhCOCH₂R¹ (R¹ = CN, CO₂Et) in EtOH containing piperidine afforded benzoylheteroarylacrylonitrile and -acrylates RCH:CR¹COPh (I). The I underwent cyclization with malononitrile to give 4H-pyrans II. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Safety of 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Safety of 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Effects of genetic polymorphism in CYP2D6, CYP2C19, and the organic cation transporter OCT1 on amitriptyline pharmacokinetics in healthy volunteers and depressive disorder patients was written by Matthaei, Johannes;Brockmoeller, Juergen;Steimer, Werner;Pischa, Konstanze;Leucht, Stefan;Kullmann, Maria;Jensen, Ole;Ouethy, Typhaine;Tzvetkov, Mladen Vassilev;Rafehi, Muhammad. And the article was included in Frontiers in Pharmacology in 2021.Synthetic Route of C23H27FN4O3 This article mentions the following:

The tricyclic antidepressant amitriptyline is frequently prescribed but its use is limited by its narrow therapeutic range and large variation in pharmacokinetics. Apart from interindividual differences in the activity of the metabolizing enzymes cytochrome P 450 (CYP) 2D6 and 2C19, genetic polymorphism of the hepatic influx transporter organic cation transporter 1 (OCT1) could be contributing to interindividual variation in pharmacokinetics. Here, the impact of OCT1 genetic variation on the pharmacokinetics of amitriptyline and its active metabolite nortriptyline was studied in vitro as well as in healthy volunteers and in depressive disorder patients. Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC₅₀ values of 28.6 and 40.4μM. Thirty other antidepressant and neuroleptic drugs were also found to be moderate to strong OCT1 inhibitors with IC₅₀ values in the micromolar range. However, in 35 healthy volunteers, preselected for their OCT1 genotypes, who received a single dose of 25 mg amitriptyline, no significant effects on amitriptyline and nortriptyline pharmacokinetics could be attributed to OCT1 genetic polymorphism. In contrast, the strong impact of the CYP2D6 genotype on amitriptyline and nortriptyline pharmacokinetics and of the CYP2C19 genotype on nortriptyline was confirmed. In addition, acylcarnitine derivatives were measured as endogenous biomarkers for OCT1 activity. The mean plasma concentrations of isobutyrylcarnitine and 2-methylbutyrylcarnitine were higher in participants with two active OCT1 alleles compared to those with zero OCT1 activity, further supporting their role as endogenous in vivo biomarkers for OCT1 activity. A moderate reduction in plasma isobutyrylcarnitine concentrations occurred at the time points at which amitriptyline plasma concentrations were the highest. In a second, independent study sample of 50 patients who underwent amitriptyline therapy of 75 mg twice daily, a significant trend of increasing amitriptyline plasma concentrations with decreasing OCT1 activity was observed (p = 0.018), while nortriptyline plasma concentrations were unaffected by the OCT1 genotype. Altogether, this comprehensive study showed that OCT1 activity does not appear to be a major factor determining amitriptyline and nortriptyline pharmacokinetics and that hepatic uptake occurs mainly through other mechanisms. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Synthetic Route of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Synthetic Route of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Infrared spectra of ion exchanges on polystyrene base was written by Strasheim, A.;Buijs, K.. And the article was included in Spectrochimica Acta in 1961.Name: 5-Methylisoxazole This article mentions the following:

The resins studied were Amberlite IRA-400 and Dowex AG-50. Dispersion media were KBr, petroleum jelly, and hexachlorobutadiene. The spectral range was 700-4000 cm.^-1 The spectrum of a polystyrene film was also obtained for comparison. Vibrational assignments were made for many bands. The functional groups do not all occupy equivalent positions in the resin. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Name: 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Name: 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data) was written by Mauri, Massimo Carlo;Franco, Gemma;Minutillo, Alessandro;Paletta, Silvia;Di Pace, Chiara;Reggiori, Alessandra;Baldelli, Sara;Cattaneo, Dario. And the article was included in Journal of Clinical Psychopharmacology in 2022.Application of 144598-75-4 This article mentions the following:

The aim of the study was a preliminary evaluation of the maintenance of clin. efficacy and tolerability of paliperidone palmitate in patients with schizophrenia during the transition phase from 1-monthly paliperidone palmitate formulation (PP1M) to PP3M, with the evaluation of plasma levels of the drug. A prospective observational study was conducted for 13 mo involving 22 outpatients, aged 18 to 66 years and clin. stabilized. Patients were affected by schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria. For each patient, clin. assessment, safety and tolerability, and drug plasma level determination were performed. Clin. efficacy was assessed by Brief Psychiatric Rating Scale, Pos. and Neg. Symptom Scale, and Hamilton Rating Scale for Depression. During the first 4 mo of the study, once-monthly paliperidone palmitate was administered, and then during the following 9 mo, the 3-monthly formulation was administered. The time course of the Brief Psychiatric Rating Scale total scores showed a statistically significant (P = 0.006) improvement from T0 to T8; Pos. and Neg. Symptom Scale scores showed a similar time course, with a statistically significant (P = 0.0016) reduction of the mean total score; Hamilton Rating Scale for Depression mean scores showed a statistically significant (P = 0.003) reduction with substantial maintenance of clin. stabilization of the patients. Only 1 patient dropped out after the first PP3M injection. Our preliminary data currently confirm the maintenance of clin. stability shifting from PP1M to PP3M. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application of 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application of 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem